Paraneoplastic neurological syndromes: a practical approach to diagnosis and management
Practical Neurology Podcast
00:00
Immunotherapy Responsive Treatments
Some of the surface directed antibodies, that's almost certainly not happening in the same way. And I can recall patients with Casper two antibodies and a tumour who only get diagnosed 18, 24 months down the line, and they get a lot better,. So I don't think there's any doubt that those patients are worth going on with treatment. Even some of the others such as Hu and Yo, which are traditionally not thought of as terribly immunotherapy responsive, may offer a chance of disease stabilisation. But also important potentially to be honest with the patients about the outcome that you can expect.
Transcript
Play full episode
